tiprankstipranks
Advertisement
Advertisement

ACXP Stock Latest News

Acurx price target lowered to $10 from $20 at Alliance Global
The FlyAcurx price target lowered to $10 from $20 at Alliance Global
15d ago
ACXP
Acurx reports Q4 EPS (73c) vs. ($3.29) last year
PremiumThe Fly
Acurx reports Q4 EPS (73c) vs. ($3.29) last year
15d ago
ACXP
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
PremiumMarket News
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
16d ago
ACXP
ACXP Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ACXP Earnings this Week: How Will it Perform?
18d ago
ACXP
Acurx Advances Ibezapolstat Program for Recurrent C. difficile
PremiumCompany Announcements
Acurx Advances Ibezapolstat Program for Recurrent C. difficile
19d ago
8K
ACXP
Acurx announces new ibezapolstat clinical trial program
PremiumThe FlyAcurx announces new ibezapolstat clinical trial program
19d ago
ACXP
Acurx files to sell 750,000 shares of common stock for holders
Premium
The Fly
Acurx files to sell 750,000 shares of common stock for holders
2M ago
ACXP
Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO
Premium
The Fly
Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO
2M ago
ACXP
One new option listing and option delistings on January 20th
PremiumThe Fly
One new option listing and option delistings on January 20th
2M ago
CVM
TEF
Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation
PremiumRatings
Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation
5M ago
ACXP
Acurx Pharmaceuticals Reports Q3 2025 Financial Results
PremiumCompany Announcements
Acurx Pharmaceuticals Reports Q3 2025 Financial Results
5M ago
ACXP
Acurx Pharmaceuticals’ Earnings Call: Achievements Amid Challenges
PremiumCompany Announcements
Acurx Pharmaceuticals’ Earnings Call: Achievements Amid Challenges
5M ago
ACXP
Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength
PremiumRatingsOptimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength
5M ago
ACXP
Acurx reports Q3 EPS ($1.23) vs. ($3.45) last year
Premium
The Fly
Acurx reports Q3 EPS ($1.23) vs. ($3.45) last year
5M ago
ACXP
Acurx announces publication of results from ibezapolstat study
Premium
The Fly
Acurx announces publication of results from ibezapolstat study
5M ago
ACXP
Is ACXP a Buy, Before Earnings?
PremiumPre-Earnings
Is ACXP a Buy, Before Earnings?
5M ago
ACXP
Acurx Pharmaceuticals’ Ibezapolstat: Promising Preclinical and Clinical Efficacy Supports Buy Rating
PremiumRatings
Acurx Pharmaceuticals’ Ibezapolstat: Promising Preclinical and Clinical Efficacy Supports Buy Rating
5M ago
ACXP
Acurx files to sell 585,000 shares of common stock for holders
PremiumThe Fly
Acurx files to sell 585,000 shares of common stock for holders
5M ago
ACXP
Acurx granted new patent for DNA Polymerase IIIC Inhibitors
PremiumThe Fly
Acurx granted new patent for DNA Polymerase IIIC Inhibitors
6M ago
ACXP
Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?
PremiumMarket NewsWhy Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?
6M ago
UPC
ACXP
Promising Outlook for Acurx Pharmaceuticals: Buy Rating Driven by Regulatory Milestones and Clinical Success of Ibezapolstat
Premium
Ratings
Promising Outlook for Acurx Pharmaceuticals: Buy Rating Driven by Regulatory Milestones and Clinical Success of Ibezapolstat
6M ago
ACXP
Acurx’s ibezapolstat receives positive EMA opinion in C. difficile infection
Premium
The Fly
Acurx’s ibezapolstat receives positive EMA opinion in C. difficile infection
6M ago
ACXP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >